RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Is your rotavirus vaccine indicated to help prevent RGE caused by G2?

RotaTeq is the only rotavirus
vaccine indicated to help
prevent RGE caused by G2

Learn About the Only Rotavirus Vaccine Indicated to Help Prevent RGE Caused by G2






RotaTeq is the only rotavirus vaccine indicated to help prevent RGE caused by G2

The Other Rotavirus Vaccine Is Only Indicated for the Prevention of RGE Caused by G1 and Non-G1 Types (G3, G4, and G9) When Administered as a 2-Dose Series

RotaTeq®
(ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT)
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Rotarix
(ROTAVIRUS VACCINE, LIVE, ORAL)4
Rotarix is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. Rotarix is approved for use in infants 6 weeks and up to 24 weeks of age.4

G2 type—genetically distinct from other common rotavirus types5,6

The 5 most common rotavirus strains belong to 2 distinct, minimally related genogroups.5,6

Wa GENOGROUP

G1P[8]G3P[8] G4P[8]G9P[8]

DS-1 GENOGROUP

G2P[4]

  • Of the common types, G1, G3, G4, and G9 are typically associated with protein P[8], while G2 is commonly associated with protein P[4].5,6
  • In other words, G2 strains generally do not share P surface proteins with the other most common rotavirus G types.5,6
Learn About the Only Rotavirus Vaccine Indicated to Help Prevent RGE Caused by G2
The Other Rotavirus Vaccine Is Only Indicated for the Prevention of RGE Caused by G1 and Non-G1 Types (G3, G4, and G9) When Administered as a 2-Dose Series
RotaTeq®
(ROTAVIRUS
VACCINE, LIVE, ORAL,
PENTAVALENT)

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
Rotarix
(ROTAVIRUS VACCINE,
LIVE, ORAL)4


Rotarix is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. Rotarix is approved for use in infants 6 weeks and up to 24 weeks of age.4
G2 type—genetically distinct from other common rotavirus types5,6

The 5 most common rotavirus strains belong to 2 distinct, minimally related genogroups.5,6

Wa GENOGROUP

G1P[8]G3P[8] G4P[8]G9P[8]

DS-1 GENOGROUP

G2P[4]

  • Of the common types, G1, G3, G4, and G9 are typically associated with protein P[8], while G2 is commonly associated with protein P[4].5,6
  • In other words, G2 strains generally do not share P surface proteins with the other most common rotavirus G types.5,6

RGE, rotavirus gastroenteritis.
Products mentioned are trademarks of their respective owners.

RGE, rotavirus gastroenteritis.
Products mentioned are trademarks of their respective owner.

ref1

Reference

  1. Centers for Disease Control and Prevention (CDC). Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States 2019. https://www.cdc.gov/vaccines/schedules/ downloads/child/0-18yrs-child-combined-schedule.pdf. Published February 22, 2019. Accessed October 22, 2019.
ref4

Reference

  1. Rotarix [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2019.
ref5

Reference

  1. Dennis AF, McDonald SM, Payne DC, et al. Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: Footprints of a globally transitioning genotype. J Virol. 2014;88(7):3789–3801.
ref6

Reference

  1. Matthijnssens J, Van Ranst M. Genotype constellation and evolution of group A rotaviruses infecting humans. Curr Opin Virol. 2012;2(4):426–433.
ref7

Reference

  1. Staat MA, Payne DC, Halasa N, et al. Continued evidence of the impact of rotavirus vaccine in children less than 3 years of age from the United States New Vaccine Surveillance Network: A multisite active surveillance program, 2006–2016. Clin Infect Dis. 2020 Feb 15. DOI: 10.1093/cid/ciaa150.

Indications and Usage for RotaTeq

RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

Infants with a history of intussusception should not receive RotaTeq.

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying Prescribing Information. The Patient Product Information also is available.

RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-ROT-00476 08/21